Vanguard Group Inc. raised its holdings in shares of Advaxis, Inc. (NASDAQ:ADXS) by 7.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,782,990 shares of the biotechnology company’s stock after acquiring an additional 119,980 shares during the period. Vanguard Group Inc. owned approximately 4.41% of Advaxis worth $11,572,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in ADXS. Bank of New York Mellon Corp lifted its stake in Advaxis by 1.9% during the 1st quarter. Bank of New York Mellon Corp now owns 183,788 shares of the biotechnology company’s stock valued at $1,501,000 after acquiring an additional 3,462 shares during the period. Parametric Portfolio Associates LLC lifted its stake in Advaxis by 116.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 86,586 shares of the biotechnology company’s stock valued at $707,000 after acquiring an additional 46,559 shares during the period. American International Group Inc. lifted its stake in Advaxis by 7.6% during the 1st quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after acquiring an additional 1,459 shares during the period. Geode Capital Management LLC lifted its stake in Advaxis by 4.8% during the 1st quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock valued at $2,286,000 after acquiring an additional 12,736 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its stake in Advaxis by 6.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 128,504 shares of the biotechnology company’s stock valued at $1,050,000 after acquiring an additional 7,353 shares during the period. Institutional investors and hedge funds own 44.07% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Vanguard Group Inc. Increases Holdings in Advaxis, Inc. (ADXS)” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/vanguard-group-inc-increases-holdings-in-advaxis-inc-adxs/1719004.html.

Advaxis, Inc. (NASDAQ ADXS) opened at $3.00 on Wednesday. Advaxis, Inc. has a 12 month low of $2.83 and a 12 month high of $10.06.

Advaxis (NASDAQ:ADXS) last posted its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $3.43 million. equities research analysts expect that Advaxis, Inc. will post -2.21 earnings per share for the current fiscal year.

In related news, insider Robert Petit sold 12,625 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,273.75. Following the completion of the sale, the insider now owns 237,265 shares of the company’s stock, valued at approximately $756,875.35. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the business’s stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $4.42, for a total transaction of $5,477,807.66. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,872,291 shares of company stock valued at $8,163,810. Company insiders own 7.21% of the company’s stock.

Several analysts have commented on ADXS shares. BidaskClub upgraded shares of Advaxis from a “hold” rating to a “buy” rating in a research note on Saturday, September 9th. HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Advaxis in a research note on Friday, September 15th. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research note on Friday, September 8th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $19.00 price objective on shares of Advaxis in a research note on Monday, September 25th.

Advaxis Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.